Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised the Swedish state in connection with its sale of shares in SAS
Mandate

Vinge has advised the Swedish state in connection with its sale of shares in SAS

October 13, 2016

Vinge has advised the Swedish state in connection with its sale of shares in SAS pursuant to a bookbuilding procedure performed on 12 October 2016.

In total, 23 million ordinary shares held by the Swedish and Norwegian governments were placed at a price of SEK 15.50 per share, equivalent to an aggregate value of approximately MSEK 357.  Following the transaction, the Swedish government holds 17.2 per cent of the ordinary shares and 17.1 per of the votes in SAS.

Vinge’s team consisted of partners Charlotte Levin and Eric Sjöman together with associates Amanda Knutsson and David Andersson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024